Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 2/2012

01.02.2012 | Original Article

Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance

verfasst von: Yongsheng Jia, Wenjian Zhang, Honglin Liu, Liang Peng, Zhihua Yang, Jinning Lou

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To explore the protective effect of KLF4 against cytotoxicity induced by cisplatin and its possible mechanisms.

Methods

The expression levels of KLF4 were detected by RT-PCR and western blot in cancer stem-like cells derived from hepatocarcinoma (T3A-A3) and the hepatocarcinoma cell line HepG2. KLF4 was knocked down in T3A-A3 by infection of pLVTHM-shKLF4 lentivirus and ectopic expressed in HepG2 by infection of pWPTS-KLF4 lentivirus. The MTT assay was carried out to determine the impact of KLF4 on cell survival in response to cisplatin. Cisplatin-induced DNA damage was measured by TUNEL staining. Glutathione content was measured by enzymatic assay. Buthionine sulfoximine was used to deplete the content of glutathione. The expression of γ-glutamylcysteine synthetase was analyzed by RT-PCR in HepG2 cells ectopic expressed KLF4.

Results

With a higher level of KLF4, T3A-A3 cells were found to be more resistant to cisplatin than HepG2 cells. KLF4 knockdown was found to reduce cisplatin resistance in T3A-A3 cells. Ectopic expression of KLF4 in HepG2 cells was found to be associated with heightened resistance to DNA damage after exposure to cisplatin. Furthermore, the content of glutathione was found to be higher in T3A-A3 cells than in HepG2 cells. A nearly twofold increase in the cellular level of glutathione was identified in HepG2 cells with ectopic expression of KLF4. This was accompanied by heightened resistance to cisplatin. KLF4-mediated resistance to cisplatin in HepG2 cells was found to be completely abrogated by treatment with buthionine sulfoximine, an inhibitor of glutathione synthesis, which did not affect the expression of KLF4. Moreover, the mRNA expression of γ-glutamylcysteine synthetase, a rate-limiting enzyme of glutathione synthesis was up-regulated by KLF.

Conclusion

We conclude that KLF4 regulates the cellular sensitivity to cisplatin in hepatocarcinoma stem-like cells and hepatocarcinoma cells by elevating intracellular glutathione levels.
Literatur
1.
Zurück zum Zitat An Y, Ongkeko WM (2009) ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 5:1529–1542PubMedCrossRef An Y, Ongkeko WM (2009) ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol 5:1529–1542PubMedCrossRef
2.
Zurück zum Zitat Fais S (2011) Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med 267:515–525CrossRef Fais S (2011) Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med 267:515–525CrossRef
3.
Zurück zum Zitat Huang G, Mills L, Worth LL (2007) Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells. Mol Cancer Ther 6:1610–1619PubMedCrossRef Huang G, Mills L, Worth LL (2007) Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells. Mol Cancer Ther 6:1610–1619PubMedCrossRef
4.
Zurück zum Zitat Varin E, Denoyelle C, Brotin E, Meryet-Figuiere M, Giffard F, Abeilard E, Goux D, Gauduchon P, Icard P, Poulain L (2010) Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 31:984–993PubMedCrossRef Varin E, Denoyelle C, Brotin E, Meryet-Figuiere M, Giffard F, Abeilard E, Goux D, Gauduchon P, Icard P, Poulain L (2010) Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 31:984–993PubMedCrossRef
5.
Zurück zum Zitat Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M, Hemminki K, Kumar R (2011) DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol [Epub ahead of print] Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M, Hemminki K, Kumar R (2011) DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol [Epub ahead of print]
6.
Zurück zum Zitat Wang GuoZ (2007) The role of sulfur in platinum anticancer chemotherapy. Anticancer Agents Med Chem 7:19–34CrossRef Wang GuoZ (2007) The role of sulfur in platinum anticancer chemotherapy. Anticancer Agents Med Chem 7:19–34CrossRef
7.
Zurück zum Zitat Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89:3070–3074PubMedCrossRef Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89:3070–3074PubMedCrossRef
8.
Zurück zum Zitat Zhang K, Chew M, Yang EB, Wong KP, Mack P (2001) Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol Pharmacol 59:837–843PubMed Zhang K, Chew M, Yang EB, Wong KP, Mack P (2001) Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol Pharmacol 59:837–843PubMed
9.
Zurück zum Zitat Anderson ME, Naganuma A, Meister A (1990) Protection against cisplatin toxicity by administration of glutathione ester. FASEB J 4:3251–3255PubMed Anderson ME, Naganuma A, Meister A (1990) Protection against cisplatin toxicity by administration of glutathione ester. FASEB J 4:3251–3255PubMed
10.
Zurück zum Zitat Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD, Cullen KJ (2000) Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol 46:255–262PubMedCrossRef Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD, Cullen KJ (2000) Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol 46:255–262PubMedCrossRef
11.
Zurück zum Zitat Alison MR, Lim SM, Nicholson LJ (2010) Cancer stem cells: problems for therapy? J Pathol 223:147–161PubMed Alison MR, Lim SM, Nicholson LJ (2010) Cancer stem cells: problems for therapy? J Pathol 223:147–161PubMed
12.
13.
Zurück zum Zitat Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676PubMedCrossRef Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676PubMedCrossRef
14.
Zurück zum Zitat Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H, Ai W (2011) Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 30:1–12 Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H, Ai W (2011) Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 30:1–12
15.
Zurück zum Zitat Rowland BD, Bernards R, Peeper DS (2005) The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 7:1074–1082PubMedCrossRef Rowland BD, Bernards R, Peeper DS (2005) The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 7:1074–1082PubMedCrossRef
16.
Zurück zum Zitat Wu LQ, Zhang WJ, Niu JX, Ye LY, Yang ZH, Grau GE, Lou JN (2008) Phenotypic and functional differences between human liver cancer endothelial cells and liver sinusoidal endothelial cells. J Vasc Res 45:78–86PubMedCrossRef Wu LQ, Zhang WJ, Niu JX, Ye LY, Yang ZH, Grau GE, Lou JN (2008) Phenotypic and functional differences between human liver cancer endothelial cells and liver sinusoidal endothelial cells. J Vasc Res 45:78–86PubMedCrossRef
17.
Zurück zum Zitat Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS (2009) MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137:647–658PubMedCrossRef Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS (2009) MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137:647–658PubMedCrossRef
18.
Zurück zum Zitat Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27:502–522PubMedCrossRef Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27:502–522PubMedCrossRef
19.
Zurück zum Zitat Chen HH, Kuo MT (2010) Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010.pii:430939 Chen HH, Kuo MT (2010) Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010.pii:430939
20.
Zurück zum Zitat Forman HJ, Zhang H, Rinna A (2009) Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med 30:1–12PubMedCrossRef Forman HJ, Zhang H, Rinna A (2009) Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med 30:1–12PubMedCrossRef
21.
Zurück zum Zitat Dudley AC, Khan ZA, Shih SC, Kang SY, Zwaans BM, Bischoff J, Klagsbrun M (2008) Calcification of multipotent prostate tumor endothelium. Cancer Cell 14:201–211PubMedCrossRef Dudley AC, Khan ZA, Shih SC, Kang SY, Zwaans BM, Bischoff J, Klagsbrun M (2008) Calcification of multipotent prostate tumor endothelium. Cancer Cell 14:201–211PubMedCrossRef
22.
Zurück zum Zitat Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111PubMedCrossRef Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111PubMedCrossRef
23.
Zurück zum Zitat Wong CW, Hou PS, Tseng SF, Chien CL, Wu KJ, Chen HF, Ho HN, Kyo S, Teng SC (2010) Kruppel-like transcription factor 4 contributes to maintenance of telomerase activity in stem cells. Stem Cells 28:1510–1517PubMedCrossRef Wong CW, Hou PS, Tseng SF, Chien CL, Wu KJ, Chen HF, Ho HN, Kyo S, Teng SC (2010) Kruppel-like transcription factor 4 contributes to maintenance of telomerase activity in stem cells. Stem Cells 28:1510–1517PubMedCrossRef
24.
Zurück zum Zitat Zhou Q, Hong Y, Zhan Q, Shen Y, Liu Z (2009) Role for Kruppel-like factor 4 in determining the outcome of p53 response to DNA damage. Cancer Res 69:8284–8292PubMedCrossRef Zhou Q, Hong Y, Zhan Q, Shen Y, Liu Z (2009) Role for Kruppel-like factor 4 in determining the outcome of p53 response to DNA damage. Cancer Res 69:8284–8292PubMedCrossRef
25.
Zurück zum Zitat Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, Kudlow JE, Lobo-Ruppert SM, Ruppert JM (2005) Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene 24:1491–1500PubMedCrossRef Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, Kudlow JE, Lobo-Ruppert SM, Ruppert JM (2005) Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene 24:1491–1500PubMedCrossRef
26.
Zurück zum Zitat Rodriguez-Garcia ME, Quiroga AG, Castro J, Ortiz A, Aller P, Mata F (2009) Inhibition of p38-MAPK potentiates cisplatin-induced apoptosis via GSH depletion and increases intracellular drug accumulation in growth-arrested kidney tubular epithelial cells. Toxicol Sci 111:413–423PubMedCrossRef Rodriguez-Garcia ME, Quiroga AG, Castro J, Ortiz A, Aller P, Mata F (2009) Inhibition of p38-MAPK potentiates cisplatin-induced apoptosis via GSH depletion and increases intracellular drug accumulation in growth-arrested kidney tubular epithelial cells. Toxicol Sci 111:413–423PubMedCrossRef
27.
Zurück zum Zitat Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H (2011) CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc(−) and Thereby Promotes Tumor Growth. Cancer Cell 19:387–400 Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H (2011) CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc(−) and Thereby Promotes Tumor Growth. Cancer Cell 19:387–400
28.
Zurück zum Zitat Noctor G, Gomez L, Vanacker H, Foyer CH (2002) Interactions between biosynthesis, compartmentation and transport in the control of glutathione homeostasis and signalling. J Exp Bot 53:1283–1304PubMedCrossRef Noctor G, Gomez L, Vanacker H, Foyer CH (2002) Interactions between biosynthesis, compartmentation and transport in the control of glutathione homeostasis and signalling. J Exp Bot 53:1283–1304PubMedCrossRef
Metadaten
Titel
Inhibition of glutathione synthesis reverses Krüppel-like factor 4-mediated cisplatin resistance
verfasst von
Yongsheng Jia
Wenjian Zhang
Honglin Liu
Liang Peng
Zhihua Yang
Jinning Lou
Publikationsdatum
01.02.2012
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 2/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-011-1708-7

Weitere Artikel der Ausgabe 2/2012

Cancer Chemotherapy and Pharmacology 2/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.